[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377254-105":59,"doc-detail-377254-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","treating-secondary-malignant-neoplasms-a-burden-of-childhood-cancer-survivors","Treating secondary malignant neoplasms: A burden of childhood cancer survivors","","Each year about 35,000 children and adolescents are diagnosed with cancer in Europe, and five-year survival now reaches around 80% in many countries. In Italy, more than 44,000 young survivors live for years after diagnosis. Long-term risk includes premature morbidity and mortality, with roughly 60% developing at least one chronic condition and over one in four experiencing severe or life-threatening disorders. Second malignant neoplasms are highlighted as the most concerning late iatrogenic sequelae. The article reports institutional screening and treatment experiences for secondary breast cancer, thyroid cancer, and osteosarcoma, emphasizing early discussion of potential late effects and management at specialized multidisciplinary centers.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treating-secondary-malignant-neoplasms-a-burden-of-childhood-cancer-survivors/377254/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treating-secondary-malignant-neoplasms-a-burden-of-childhood-cancer-survivors/377254.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the article emphasize specialized multidisciplinary centers and early discussion?","Question",{"text":112,"@type":113},"It argues that surveillance and management of potential late problems are crucial for future health and that survivors who develop second malignant neoplasms should be treated in highly specialized centers with close multidisciplinary communication.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},377254,1790654266,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":131,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":67,"update_tm":135,"read_time":136},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Editorial  \nTj  \nTumori journal  \nTreating secondary malignant neoplasms: A burden of childhood cancer survivors  \nMarta G Podda 1*, Cristina Meazza 1*, Giovanna Gattuso 1, Giovanna Sironi 1, Olga Nigro 1, Luca Bergamaschi 1, Veronica Biassoni 1, Michela Casanova 1, Stefano Chiaravalli 1, Andrea Ferrari 1, Roberto Luksch 1, Nadia Puma 1, Elisabetta Schiavello 1, Filippo Spreafico 1, Paolo Grampa2, Siranoush Manoukian3, Sabina Vennarini4, Paola Collini5, Primo A Daolio6, Massimiliano Gennaro7, Marco Guzzo8, Carlo Morosi9, Davide Biasoni 10, Maura Massimino 1\\# and Monica Terenziani 1\\#  \nTumori Journal  \n2023, Vol. 109(5) 436–441 © Fondazione IRCCS Istituto Nazionale dei Tumori 2023  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/03008916231160824](DOI: 10.1177/03008916231160824)[ ](DOI: 10.1177/03008916231160824)[journals.sagepub.com/home/tmj](journals.sagepub.com/home/tmj)  \nAbstract  \nEach year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combination of chemotherapy, radiotherapy, and surgery. To date, there are more than 44,000 Italians still living several years after being diagnosed with cancer in developmental age. The risk of premature morbidity and mortality for cancer survivors is well known and documented. Approximately 60% of survivors of cancer in childhood and adolescence have at least one chronic health condition in later life, and more than one in four develop severe or life-threatening disorders. Among the various long-term iatrogenic sequelae of cancer treatments, the most worrisome are second malignant neoplasms. We reported on our mono-institutional experiences of screening and treating secondary breast cancer, secondary thyroid cancer and secondary osteosarcoma. Recommendations on the surveillance needed for cancer survivors because of the risk of late effects of their disease or its treatment suggest that discussing the potential problems early on can be crucial to a patient’s future health. These considerations and our consolidated experience strengthen our conviction that survivors of cancer in childhood and adolescence who develop second malignant neoplasms should be treated at highlyspecialized centers. Multidisciplinary care requires close communications and high levels of up-to-date professional expertise. This challenging area of health care is also changing rapidly because cancer survivorship is a work in progress, but we cannot wait for definitive conclusions on many aspects because this will take decades, especially for pediatric patients.  \nKeywords  \nSecond cancer, long-term survivors, iatrogenic sequelae  \nDate received: 24 January 2023; accepted: 11 February 2023  \n1 Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n2Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n3Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n4Radiotherapy Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n5Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n6C.O.O., Azienda Socio Sanitaria Territoriale Gaetano Pini, Milan, Italy 7Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n8Head and Neck Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n9Radiology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy  \n10Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy  \n*These authors contributed equally to this work as co-first authors.  \n\\#These authors contributed equally to this work as co-last authors.  \nCorresponding author:  \nMonica Terenziani, Pediatric","cbCainqLGdioGoX8","https://ap.wps.com/l/cbCainqLGdioGoX8","pdf",646594,"English","# Abstract\n# Keywords\n# Introduction\n## Survival rates and survivor burden in Europe\n## Italian survivor numbers and long-term follow-up need","[{\"question\":\"Why does the article emphasize specialized multidisciplinary centers and early discussion?\",\"answer\":\"It argues that surveillance and management of potential late problems are crucial for future health and that survivors who develop second malignant neoplasms should be treated in highly specialized centers with close multidisciplinary communication.\"}]","Treating secondary malignant neoplasms: A burden of childhood cancer survivors | PDF",1790223958,15]